NDLI: MYC and human telomerase gene (TERC) copy number gain in early-stage non-small cell lung cancer.

Please wait, while we are loading the content...

The effect of smoking and major vein resection on post-therapy lymphedema in soft tissue sarcomas treated with neoadjuvant radiation and limb-salvage surgery.

Age and genetics: how do prognostic factors at diagnosis explain disparities in acute myeloid leukemia?

The Cleveland Clinic experience with primary central nervous system lymphoma.

CMF-regimen preferred as first-course chemotherapy for older and sicker women with breast cancer: Findings from a SEER-Medicare-based population study.

Breast conservation therapy utilizing partial breast brachytherapy for early-stage cancer of the breast: a retrospective review from the Saint Luke's Cancer Institute.

Direct percutaneous transhepatic portomesenteric venous stenting in management of locally advanced pancreatic cancer.

A comparison between the Chinese 2008 and the 7th edition AJCC staging systems for nasopharyngeal carcinoma.

Concurrent involved-field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence.

The association between tumor epidermal growth factor receptor (EGFR) mutation and multiple primary malignancies in patients with adenocarcinoma of the lungs.

Decision making and factors influencing long-term satisfaction with prophylactic mastectomy in women with breast cancer.

Advances in the management of recurrent endometrial cancer.

Retroperitoneal liposarcoma: a comprehensive review.

ACR Appropriateness Criteria® Induction and Adjuvant Therapy for N2 Non–small-cell Lung Cancer

MYC and human telomerase gene (TERC) copy number gain in early-stage non-small cell lung cancer.

Squamous non-small cell lung cancer as a distinct clinical entity.

Efficacy of Oxaliplatin-based Chemotherapy+Bevacizumab as First-line Treatment for Advanced Colorectal Cancer: A Systematic Review and Pooled Analysis of Published Trials

Year: 2015 Volume: 38 Issue: 1

Year: 2014 Volume: 37

Year: 2013 Volume: 36

Year: 2012 Volume: 35

Year: 2011 Volume: 34

Year: 2010 Volume: 33

Year: 2009 Volume: 32

Year: 2008 Volume: 31

Year: 2007 Volume: 30

MYC and human telomerase gene (TERC) copy number gain in early-stage non-small cell lung cancer.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Flacco, Antonella Ludovini, Vienna Bianconi, Fortunato Ragusa, Mark Bellezza, Guido Tofanetti, Francesca R. Pistola, Lorenza Siggillino, Annamaria Vannucci, Jacopo Cagini, Lucio Sidoni, Angelo Puma, Francesco Varella-Garcia, Marileila Crinò, Lucio
Description	Country affiliation: Colombia Author Affiliation: Flacco A ( *Department of Medical Oncology, S. Maria della Misericordia Hospital Departments of Electronic and Information Engineering Thoracic Surgery §Institute of Pathological Anatomy and Histology, University of Perugia, Perugia, Italy â¥Department of Medicine/Medical Oncology, University of Colorado Cancer Center, Aurora, CO.)
Abstract	OBJECTIVES: We investigated the frequency of MYC and TERC increased gene copy number (GCN) in early-stage non-small cell lung cancer (NSCLC) and evaluated the correlation of these genomic imbalances with clinicopathologic parameters and outcome. MATERIALS AND METHODS: Tumor tissues were obtained from 113 resected NSCLCs. MYC and TERC GCNs were tested by fluorescence in situ hybridization (FISH) according to the University of Colorado Cancer Center (UCCC) criteria and based on the receiver operating characteristic (ROC) classification. RESULTS: When UCCC criteria were applied, 41 (36%) cases for MYC and 41 (36%) cases for TERC were considered FISH-positive. MYC and TERC concurrent FISH-positive was observed in 12 cases (11%): 2 (17%) cases with gene amplification and 10 (83%) with high polysomy. By using the ROC analysis, high MYC (mean ≥ 2.83 copies/cell) and TERC (mean ≥ 2.65 copies/cell) GCNs were observed in 60 (53.1%) cases and 58 (51.3%) cases, respectively. High TERC GCN was associated with squamous cell carcinoma (SCC) histology (P=0.001). In univariate analysis, increased MYC GCN was associated with shorter overall survival (P=0.032 [UCCC criteria] or P=0.02 [ROC classification]), whereas high TERC GCN showed no association. In multivariate analysis including stage and age, high MYC GCN remained significantly associated with worse overall survival using both the UCCC criteria (P=0.02) and the ROC classification (P=0.008). CONCLUSIONS: Our results confirm MYC as frequently amplified in early-stage NSCLC and increased MYC GCN as a strong predictor of worse survival. Increased TERC GCN does not have prognostic impact but has strong association with squamous histology.
File Format	HTM / HTML
ISSN	02773732
e-ISSN	1537453X
DOI	10.1097/COC.0000000000000012
Journal	American Journal of Clinical Oncology
Issue Number	2
Volume Number	38
Language	English
Publisher	Lippincott Williams & Wilkins
Publisher Date	2015-04-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Discipline Oncology Carcinoma, Non-small-cell Lung Genetics Gene Dosage Genes, Myc Lung Neoplasms Telomerase Area Under Curve Mortality Pathology Disease-free Survival In Situ Hybridization, Fluorescence Kaplan-meier Estimate Neoplasm Staging Proportional Hazards Models Roc Curve Retrospective Studies Research Support, N.i.h., Extramural Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

MYC and Human Telomerase Gene (TERC) Copy Number Gain in Early-stage Non–small Cell Lung Cancer

The impact of hyperfractionated radiotherapy regimen in patients with non-small cell lung cancer.

FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.

Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer.

Reirradiation for locoregionally recurrent lung cancer: outcomes in small cell and non-small cell lung carcinoma.

AP4 predicts poor prognosis in nonsmall cell lung cancer.

AC133 expression associated with poor prognosis in stage II colorectal cancer.

Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer.

Prognosis of small-cell lung cancer since the introduction of amrubicin.

MYC and human telomerase gene (TERC) copy number gain in early-stage non-small cell lung cancer.

Similar Documents

MYC and Human Telomerase Gene (TERC) Copy Number Gain in Early-stage Non–small Cell Lung Cancer

The impact of hyperfractionated radiotherapy regimen in patients with non-small cell lung cancer.

FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.

Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer.

Reirradiation for locoregionally recurrent lung cancer: outcomes in small cell and non-small cell lung carcinoma.

AP­4 predicts poor prognosis in non­small cell lung cancer.

AC133 expression associated with poor prognosis in stage II colorectal cancer.

Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer.

Prognosis of small-cell lung cancer since the introduction of amrubicin.

MYC and human telomerase gene (TERC) copy number gain in early-stage non-small cell lung cancer.

AP4 predicts poor prognosis in nonsmall cell lung cancer.